United States COVID-19 Vaccine Market Set for Transformative Growth Driven by Innovation, Strategic Collaborations, and Expanding Immunization Programs 2025 | Top key players - Pfizer/BioNTech, Moderna, Inc., AstraZeneca.

Market Size and Growth:

The Global COVID-19 Vaccine Market size reached US$ 13.43 billion in 2024 and is expected to reach US$ 29.98 billion by 2033, growing at a CAGR of 9.8% during the forecast period 2025-2033.

The COVID-19 Vaccine Market report by DataM Intelligence provides insights into the latest trends and developments in the market. This report identifies the key growth opportunities in the market and provides recommendations for market participants to capitalize on these opportunities. Overall, the COVID-19 Vaccine market report is an essential resource for market participants who are looking to gain a comprehensive understanding of the market and identify opportunities for growth.

Download a Free sample PDF (Use Corporate email ID to Get Higher Priority) at: https://datamintelligence.com/download-sample/covid-19-vaccine-market?sz

The COVID-19 Vaccine Market refers to the global industry focused on the research, development, production, distribution, and commercialization of vaccines designed to prevent COVID-19 infection. It encompasses various vaccine platforms, including mRNA, viral vector, protein subunit, and inactivated vaccines. The market is driven by ongoing vaccination campaigns, booster demand, evolving virus variants, and government-led immunization initiatives worldwide.

Recent Key Developments of United States (U.S):

New Vaccine Approvals: The FDA approved updated versions of the Pfizer-BioNTech and Novavax COVID-19 vaccines for the 2025-2026 season. These new formulations are adapted to target the circulating LP.8.1 variant, a sublineage of JN.1. The approvals were for specific populations, including adults aged 65 and older and individuals ages 5 through 64 with increased risk for severe COVID-19. (August-September 2025)

Clinical Trial Data: Pfizer and BioNTech released positive Phase 3 clinical trial data for their 2025-2026 vaccine formula, showing at least a four-fold increase in neutralizing antibodies against the LP.8.1 sublineage in older adults and those with underlying conditions. (September 2025)

Moderna's Preliminary Data: Moderna announced promising preliminary immunogenicity data for its 2025-2026 Spikevax vaccine formulation, also targeting the LP.8.1 variant. The data showed a greater than eight-fold increase in neutralizing antibodies. (September 2025)

Insurance Coverage: A major insurance industry trade group, AHIP, announced it would continue to cover updated COVID-19 vaccines and flu vaccines through the end of 2026, with no cost-sharing for patients. This came amid uncertainty about federal recommendations and coverage. (September 2025)

State-Level Guidance: In response to federal-level policy changes and a perceived lack of clear federal guidance, several states, including those in the West Coast Health Alliance (California, Oregon, Washington, Hawaii), issued their own unified, science-based vaccine recommendations for the upcoming season. (September 2025)

Key Players:

Pfizer/BioNTech
Moderna, Inc.
AstraZeneca.
Johnson & Johnson (Janssen Scientific Affairs, LLC)
SINOVAC
CanSino Biologics Inc.
Novavax.
Sanofi/GSK
Beijing Institute of Biological Products Co., Ltd.
Serum Institute of India Pvt. Ltd.
Gamaleya Research Institute.

This Report Covers:

✔ Go-to-market Strategy.

✔ Neutral perspective on the market performance.

✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.

✔Customized regional/country reports as per request and country level analysis.

✔ Potential & niche segments and regions exhibiting promising growth covered.

✔ Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=covid-19-vaccine-market

Market Segmentation:

By Infection Type: SARS-CoV-2, HCoVs, Others.

By Vaccine Type: mRNA Vaccines, Viral Vector Vaccines, Inactivated Virus Vaccines, Protein Subunit Vaccines, Live Attenuated Vaccines, Others.

By Route of Administration: Intramuscular, Subcutaneous, Oral.

By Age Group: Below 18 Years, Above 18 Years.

By End-User: Hospitals, Specialty Clinics, Others.

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/covid-19-vaccine-market?sz

Chapter Outline

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, COVID-19 Vaccine market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global COVID-19 Vaccine Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global COVID-19 Vaccine market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the COVID-19 Vaccine Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the COVID-19 Vaccine Market in 2025?
◆ What is the projected growth rate of the COVID-19 Vaccine Market through 2033?
◆ Who are the key players in the COVID-19 Vaccine Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.